At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Liposomal bupivacaine 88 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Cumulative Opioid Consumption After Interscalene Brachial Plexus Block With Liposomal Bupivacaine (Exparel; 88 mg in 20 cc) Versus Bupivacaine 0.25% for Arthroscopic Shoulder Surgery
In Brief
A Phase 4 clinical trial evaluating Liposomal bupivacaine and Bupivacaine 0.25% for Shoulder Pain and Rotator Cuff Tear. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the quality and duration of pain relief after shoulder surgery provided by a single injection of liposomal bupivacaine versus standard bupivacaine when administered as an interscalene brachial plexus block. It is hypothesized that the liposomal bupivacaine formulation will provide more effective pain relief than standard bupivacaine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShoulder Pain, Rotator Cuff Tear
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartJan 2014
Primary CompletionFeb 2015
TodayJul 2026
First PostedNov 6, 2013
Enrollment StartJan 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.7 years ago
Interventions
Liposomal bupivacainedrug
liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
Bupivacaine 0.25%drug
20 cc of bupivacaine 0.25%